Trastuzumab-MCC-DM1 Conjugate
Cancer Terms ->
Drugs and Chemicals ->
Pharmacologic Substance ->
Biological Response Modifier ->
Immunoconjugate -> Trastuzumab-MCC-DM1 Conjugate
Trastuzumab-MCC-DM1 Conjugate Definition
An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.
Trastuzumab-MCC-DM1 Conjugate Synonyms
Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1 Immunoconjugate
Terms in Trastuzumab-MCC-DM1 Conjugate category
Copyright © Cancer Terms 2014 All rights reserved. | Terms of Use | Low Carb Foods
No reproduction or republication permitted.